John L Knopf

USPTO Granted Patents = 86 (Patent Applications = 43)

CIPO Patents = 9 (Patent Applications = 12)

EPO Patents = 28 (Patent Applications = 33)

Average Co-Inventor Count = 2.7

ph-index = 23

Forward Citations = 1,388(Granted Patents)

Inventors with similar research interests:

Location History:

Acton, MA (US) (1994 - 2005)
Carlisle, MA (US) (2008 - 2023)
Cambridge, MA (US) (2019 - 2024)

Company Filing History:

75 out of 167

Acceleron Pharma Inc.

patents

9 out of 389

Genetics Institute, Inc.

Ludwig Institute for Cancer Research Limited

where one patent can have more than one assignee

Years Active: 1994-2025

Loading Chart...

86 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365736 - ALK7 binding proteins and uses thereof (2025-07-22),

2. 12343378 - Compositions and methods for treating pulmonary hypertension (2025-07-01),

3. 12144860 - ALK1 receptor and ligand antagonists and uses thereof (2024-11-19),

4. 12024563 - ALK7 antagonists and uses thereof (2024-07-02),

5. 11827689 - ALK7:ActRIIB heteromultimers and uses thereof (2023-11-28),

6. 11807673 - Methods and compositions for increasing red blood cells (2023-11-07),

7. 11708414 - ALK7 binding proteins and uses thereof (2023-07-25),

8. 11622992 - Compositions and methods for treating pulmonary hypertension (2023-04-11),

9. 11497794 - Compositions and methods for treating pulmonary hypertension (2022-11-15),

10. 11318188 - Compositions and methods for treating pulmonary hypertension (2022-05-03),

11. 11219666 - Compositions and methods for treating pulmonary hypertension (2022-01-11),

12. 11129873 - Method for promoting bone growth using activin-actriia antagonists (2021-09-28),

13. 11065303 - Compositions and methods for treating pulmonary hypertension (2021-07-20),

14. 11059894 - ALK7 binding proteins and uses thereof (2021-07-13),

15. 11028145 - ALK7:actriib heteromultimers and uses thereof (2021-06-08),

Title: A Spotlight on John L. Knopf: Innovations in Biomedical Research

Introduction: John L. Knopf, based in Acton, MA, has made significant contributions to the field of biomedical research, holding a remarkable total of 84 patents. His innovative work focuses on understanding and manipulating key biological processes related to angiogenesis and metabolic health.

Latest Patents: Among his latest patents, two significant inventions stand out. The first, titled "ALK1 receptor and ligand antagonists and uses thereof," explores the potential of a polypeptide that targets the activin-like kinase I (ALK1) protein to inhibit angiogenesis. This discovery has implications for treating various angiogenesis-related disorders in mammals. The second patent, "ALK7 antagonists and uses thereof," provides methods to utilize ALK7 antagonists for improving metabolic parameters and addressing kidney-associated diseases and certain types of cancer in patients.

Career Highlights: John L. Knopf has had an impressive career, having worked with notable companies such as Acceleron Pharma Inc. and Genetics Institute, Inc. His expertise and leadership in research have driven forward the development of innovative therapies and treatments.

Collaborations: Throughout his career, Knopf has collaborated with esteemed professionals in the field, including Jasbir S. Seehra and Ravindra Kumar. These partnerships have played a pivotal role in advancing his research and expanding the impact of his innovations.

Conclusion: John L. Knopf's prolific output of patents and his commitment to innovation underscore his vital role in the biomedical research community. His work not only contributes to scientific understanding but also paves the way for new therapeutic approaches that could have a lasting impact on health care.

This text is generated by artificial intelligence and may not be accurate.